Multi-dimensional analysis reveals the potential of PDK4 as a tumor biomarker and target for immunotherapy.
1/5 보강
[PURPOSE] To explore the clinical significance of pyruvate dehydrogenase kinase 4 (PDK4) in pan-cancer and its potential as a tumor biomarker and immunotherapy target.
APA
Deng Y, Wang X, et al. (2026). Multi-dimensional analysis reveals the potential of PDK4 as a tumor biomarker and target for immunotherapy.. Discover oncology, 17(1). https://doi.org/10.1007/s12672-026-04656-3
MLA
Deng Y, et al.. "Multi-dimensional analysis reveals the potential of PDK4 as a tumor biomarker and target for immunotherapy.." Discover oncology, vol. 17, no. 1, 2026.
PMID
41729388 ↗
Abstract 한글 요약
[PURPOSE] To explore the clinical significance of pyruvate dehydrogenase kinase 4 (PDK4) in pan-cancer and its potential as a tumor biomarker and immunotherapy target.
[METHODS] Public databases (HPA, TCGA, GTEx, etc.) were used to analyze PDK4 expression, diagnostic efficacy, prognostic value, immune characteristics, genetic alterations, and immunotherapy responsiveness in pan-cancer. Targeted drugs were predicted via molecular docking.
[RESULTS] PDK4 is predominantly expressed in skeletal muscle and specific cell types (basal prostatic cells, skeletal myocytes, etc.) in normal tissues. In most tumors, PDK4 expression is downregulated, with high diagnostic efficacy (AUC > 0.7 for most cancers) and independent prognostic value for overall survival (OS) in multiple tumors. PDK4 is enriched in immune cells (monocytes, myeloid DC) and positively correlated with immune infiltration and checkpoint genes. High PDK4 expression improves progression-free survival (PFS) in anti-PD-L1-treated patients, and tretinoin binds stably to PDK4.
[CONCLUSIONS] PDK4 is a promising pan-cancer diagnostic/prognostic biomarker and potential immunotherapy target, providing a basis for personalized cancer treatment.
[METHODS] Public databases (HPA, TCGA, GTEx, etc.) were used to analyze PDK4 expression, diagnostic efficacy, prognostic value, immune characteristics, genetic alterations, and immunotherapy responsiveness in pan-cancer. Targeted drugs were predicted via molecular docking.
[RESULTS] PDK4 is predominantly expressed in skeletal muscle and specific cell types (basal prostatic cells, skeletal myocytes, etc.) in normal tissues. In most tumors, PDK4 expression is downregulated, with high diagnostic efficacy (AUC > 0.7 for most cancers) and independent prognostic value for overall survival (OS) in multiple tumors. PDK4 is enriched in immune cells (monocytes, myeloid DC) and positively correlated with immune infiltration and checkpoint genes. High PDK4 expression improves progression-free survival (PFS) in anti-PD-L1-treated patients, and tretinoin binds stably to PDK4.
[CONCLUSIONS] PDK4 is a promising pan-cancer diagnostic/prognostic biomarker and potential immunotherapy target, providing a basis for personalized cancer treatment.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- OTU deubiquitinases in disease: roles and targeting.
- Mechanism of d-Glucaro-1,4-lactone enhancing the anticancer efficacy of lenvatinib via the IFN-γ-STAT3-PD-L1 signaling pathway in hepatocellular carcinoma.
- Bioresponsive immunomodulator nanocomplex for selective immunoengineering in metastatic lymph nodes.
- DNAJB6 as an immuno-oncogenic hub in liver hepatocellular carcinoma: multi-omic profiling reveals prognostic significance and therapeutic vulnerability.
- Association between frailty and the risks of chronic pulmonary diseases and lung cancer.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy.
- Novel roles of SETD2 in tumor metabolism and immunotherapy: a systematic review and meta-analysis.
- Negative trial but positive lesson: reframing immunotherapy resistance from one-size-fits-all to precision strategies.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Chalcone-containing dual-targeting PD-L1/tubulin small molecules: a novel approach for cancer immunotherapy.
- Copper-enriched zinc peroxides induced cuproptosis through concurrent metabolic and oxidative dysregulation for boosting immunotherapy in colorectal cancer.